When open the 72,000 sq ft research and development facility in Ridgefield, Connecticut will supply Boehringer with active pharmaceutical ingredients (APIs) needed in early development. Projects will then transfer to sites in Ohio, Virginia, Germany and Italy as they are scaled up.
Boehringer also highlighted its other US investments. “These are exciting projects; ones that increase Boehringer Ingelheim's research and development capabilities and reinforce our commitment to growth and innovation in the US”, J Martin Carroll, president and CEO of Boehringer in the US, said.